Schizophrenia Clinical Trial
Official title:
Transcranial Direct Current Stimulation (tDCS)and Cognitive Processing
Verified date | March 2023 |
Source | Johns Hopkins University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This research is being done to determine whether transcranial direct current stimulation (tDCS) can improve certain mental abilities. In this research, battery powered device is used to deliver very weak electrical current to the surface of the scalp while participants complete cognitive tasks. Our aim is to find out whether tDCS will improve task performance in both healthy adults and those with neurological impairment.
Status | Completed |
Enrollment | 307 |
Est. completion date | March 2, 2023 |
Est. primary completion date | December 23, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 79 Years |
Eligibility | Eligibility Criteria by Study Group Normal Controls Inclusion Criteria: - Right handed (as determined by the Edinburgh battery) - English as native language Normal Controls Exclusion Criteria: - Appreciable deficits in hearing - Appreciable problems with articulation - Schizophrenia, bipolar disorder, or major depression - Appreciable accent - Any neurological disorder associated with cognitive impairment or neuroanatomic abnormality - Language-based learning disorder - Any implanted metal device (precludes use of tDCS) - Any implanted cardiac pacemaker - Dementia or Mini-Mental State Exam < 24 - Estimated verbal intelligence < 70 Aphasia Group Inclusion Criteria: - Right handed (as determined by the Edinburgh battery) - English as native language - History of acquired left-hemisphere dysfunction Aphasia Group Exclusion Criteria: - Appreciable deficits in hearing - Schizophrenia, bipolar disorder, or major depression - Appreciable accent - Language-based learning disorder - Any implanted metal device - Any implanted cardiac pacemaker - Mini-Mental State Exam < 21/27 (omitting naming & items) - Estimated verbal intelligence < 70 Schizophrenia/First-degree Family Members Inclusion Criteria: - Right handed (as determined by the Edinburgh battery) - English as native language - Diagnosis of schizophrenia (SZ) or bipolar disorder (BD) - First degree family member of individual with SZ or BD Schizophrenia/First-degree Family Members Exclusion Criteria: - Appreciable deficits in hearing - Appreciable accent - Any implanted metal device (precludes use of tDCS) - Any implanted cardiac pacemaker - Dementia or Mini-Mental State Exam < 24 - Estimated verbal intelligence < 70 High-functioning Autism Inclusion Criteria: - Right handed (as determined by the Edinburgh battery) - English as native language - Diagnosis of High-functioning autism (i.e., Asperger's) High-functioning Autism Exclusion Criteria: - Appreciable deficits in hearing - Schizophrenia, bipolar disorder, or major depression - Appreciable accent - Any implanted metal device - Any implanted cardiac pacemaker - Dementia or Mini-Mental State Exam < 24 - Estimated verbal intelligence < 70 |
Country | Name | City | State |
---|---|---|---|
United States | Department of Neurology; Cognitive Neurology/Neuropsychology | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
Johns Hopkins University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Indices of cognitive function | The average time frame is 1 hour | ||
Secondary | Persistence of cognitive enhancements following tDCS | The average time frame is 1 hour | ||
Secondary | Initiation, endurance and cessation of skin sensations caused by tDCS | The initiation, endurance and cessation of skin sensations caused by tDCS will be examined in order to develop a more effective blinding procedure. | The average time frame is 1 hour |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |